Congenital Hyperinsulinism clinical trials at UCSF
1 research study open to new patients
open to eligible people ages up to 12 months
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children < 1 year of age with congenital hyperinsulinism.
San Francisco, California and other locations